Cargando…
Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in recent drug discovery that involves the combination of two drug pharmacophores into a single molecule. The hybrid...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500727/ https://www.ncbi.nlm.nih.gov/pubmed/36145292 http://dx.doi.org/10.3390/ph15091071 |
_version_ | 1784795292661448704 |
---|---|
author | Singh, Ankit Kumar Kumar, Adarsh Singh, Harshwardhan Sonawane, Pankaj Paliwal, Harshali Thareja, Suresh Pathak, Prateek Grishina, Maria Jaremko, Mariusz Emwas, Abdul-Hamid Yadav, Jagat Pal Verma, Amita Khalilullah, Habibullah Kumar, Pradeep |
author_facet | Singh, Ankit Kumar Kumar, Adarsh Singh, Harshwardhan Sonawane, Pankaj Paliwal, Harshali Thareja, Suresh Pathak, Prateek Grishina, Maria Jaremko, Mariusz Emwas, Abdul-Hamid Yadav, Jagat Pal Verma, Amita Khalilullah, Habibullah Kumar, Pradeep |
author_sort | Singh, Ankit Kumar |
collection | PubMed |
description | Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in recent drug discovery that involves the combination of two drug pharmacophores into a single molecule. The hybrid molecule acts through distinct modes of action on several targets at a given time with more efficacy and less susceptibility to resistance. Thus, there is a huge scope for using hybrid compounds to tackle the present difficulties in cancer medicine. Recent work has applied this technique to uncover some interesting molecules with substantial anticancer properties. In this study, we report data on numerous promising hybrid anti-proliferative/anti-tumor agents developed over the previous 10 years (2011–2021). It includes quinazoline, indole, carbazole, pyrimidine, quinoline, quinone, imidazole, selenium, platinum, hydroxamic acid, ferrocene, curcumin, triazole, benzimidazole, isatin, pyrrolo benzodiazepine (PBD), chalcone, coumarin, nitrogen mustard, pyrazole, and pyridine-based anticancer hybrids produced via molecular hybridization techniques. Overall, this review offers a clear indication of the potential benefits of merging pharmacophoric subunits from multiple different known chemical prototypes to produce more potent and precise hybrid compounds. This provides valuable knowledge for researchers working on complex diseases such as cancer. |
format | Online Article Text |
id | pubmed-9500727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95007272022-09-24 Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids Singh, Ankit Kumar Kumar, Adarsh Singh, Harshwardhan Sonawane, Pankaj Paliwal, Harshali Thareja, Suresh Pathak, Prateek Grishina, Maria Jaremko, Mariusz Emwas, Abdul-Hamid Yadav, Jagat Pal Verma, Amita Khalilullah, Habibullah Kumar, Pradeep Pharmaceuticals (Basel) Review Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in recent drug discovery that involves the combination of two drug pharmacophores into a single molecule. The hybrid molecule acts through distinct modes of action on several targets at a given time with more efficacy and less susceptibility to resistance. Thus, there is a huge scope for using hybrid compounds to tackle the present difficulties in cancer medicine. Recent work has applied this technique to uncover some interesting molecules with substantial anticancer properties. In this study, we report data on numerous promising hybrid anti-proliferative/anti-tumor agents developed over the previous 10 years (2011–2021). It includes quinazoline, indole, carbazole, pyrimidine, quinoline, quinone, imidazole, selenium, platinum, hydroxamic acid, ferrocene, curcumin, triazole, benzimidazole, isatin, pyrrolo benzodiazepine (PBD), chalcone, coumarin, nitrogen mustard, pyrazole, and pyridine-based anticancer hybrids produced via molecular hybridization techniques. Overall, this review offers a clear indication of the potential benefits of merging pharmacophoric subunits from multiple different known chemical prototypes to produce more potent and precise hybrid compounds. This provides valuable knowledge for researchers working on complex diseases such as cancer. MDPI 2022-08-28 /pmc/articles/PMC9500727/ /pubmed/36145292 http://dx.doi.org/10.3390/ph15091071 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Singh, Ankit Kumar Kumar, Adarsh Singh, Harshwardhan Sonawane, Pankaj Paliwal, Harshali Thareja, Suresh Pathak, Prateek Grishina, Maria Jaremko, Mariusz Emwas, Abdul-Hamid Yadav, Jagat Pal Verma, Amita Khalilullah, Habibullah Kumar, Pradeep Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title | Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title_full | Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title_fullStr | Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title_full_unstemmed | Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title_short | Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids |
title_sort | concept of hybrid drugs and recent advancements in anticancer hybrids |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500727/ https://www.ncbi.nlm.nih.gov/pubmed/36145292 http://dx.doi.org/10.3390/ph15091071 |
work_keys_str_mv | AT singhankitkumar conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT kumaradarsh conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT singhharshwardhan conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT sonawanepankaj conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT paliwalharshali conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT tharejasuresh conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT pathakprateek conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT grishinamaria conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT jaremkomariusz conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT emwasabdulhamid conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT yadavjagatpal conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT vermaamita conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT khalilullahhabibullah conceptofhybriddrugsandrecentadvancementsinanticancerhybrids AT kumarpradeep conceptofhybriddrugsandrecentadvancementsinanticancerhybrids |